Bremelanotide acetate - Generic Drug Details

What are the generic drug sources for bremelanotide acetate and what is the scope of freedom to operate?

Bremelanotide acetate is the generic ingredient in one branded drug marketed by Cosette and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bremelanotide acetate has twenty-nine patent family members in twenty-three countries.

Two suppliers are listed for this compound.

Summary for bremelanotide acetate

International Patents:	29
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	1
Patent Applications:	36
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bremelanotide acetate
DailyMed Link:	bremelanotide acetate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bremelanotide acetate

Constraining patent/regulatory exclusivity:

9,352,013

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for bremelanotide acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Palatin Technologies, Inc	Phase 2

See all bremelanotide acetate clinical trials

Pharmacology for bremelanotide acetate

Drug Class	Melanocortin Receptor Agonist
Mechanism of Action	Melanocortin Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for bremelanotide acetate

G02CX	Other gynecologicals
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for bremelanotide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	9,352,013
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	10,286,034
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	11,590,209

Expired US Patents for bremelanotide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019	6,579,968
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019	6,794,489

International Patents for bremelanotide acetate

Country	Patent Number	Title	Estimated Expiration
Georgia, Republic of	P20196947	BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION
Hong Kong	1211227	用於女性性功能障礙的佈雷默浪丹療法 (BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION)
Mexico	362610	USOS DE BREMELANOTIDA EN TERAPIA PARA LA DISFUNCIÓN SEXUAL FEMENINA. (BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION.)

Market Dynamics and Financial Trajectory for Bremelanotide Acetate

Last updated: February 16, 2026

Summary

Bremelanotide acetate, marketed as Vyleesi, is a peptide-based drug approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Since its approval by the FDA in June 2019, the drug’s market penetration has been limited, constrained by regulatory, competitive, and prescriber challenges. The overall revenue trajectory remains uncertain, with growth prospects tied to increased awareness, expanding indications, and pharmaceutical marketing strategies.

---

What is the Current Market Position of Bremelanotide Acetate?

Bremelanotide Acetate entered a niche market with limited competition. Its primary competitor within female sexual dysfunction (FSD) remedies remains flibanserin (Addyi). According to reports, Vyleesi generated approximately $15 million globally in 2021, with sales concentrated in North America. Data from IQVIA indicates that initial FDA approval drove a modest launch impact, but sales plateaued due to poor awareness and limited physician adoption.

What Are the Key Drivers and Barriers Affecting Its Market Penetration?

Drivers:

• Regulatory approval in multiple regions: Vyleesi received approval in the United States, with plans for expansion into other markets based on regulatory pathways.

• Limited effective alternatives for HSDD: The primary competitor, flibanserin, has safety concerns that may favor bremeletonide's profile if marketed adequately.

• Growing awareness of female sexual health: Increasing acceptance of female sexual dysfunction as a legitimate medical condition can drive demand.

Barriers:

• Limited physician familiarity and prescribing habits: Many gynecologists and primary care physicians remain hesitant due to safety profile concerns and lack of familiarity.

• Side effect profile: Adverse events like nausea and adverse cardiovascular effects limit widespread use.

• High treatment costs: As a peptide drug requiring subcutaneous administration, the cost burden may restrict patient access.

• Market skepticism: Past failures in FSD treatments, such as flibanserin's sales struggles, temper investment enthusiasm.

How Does Bremelanotide Acetate’s Financial Trajectory Compare to Other Female Sexual Dysfunction Drugs?

Sales Performance:

Drug	Released	2021 Revenue (USD)	Market Penetration
Bremelanotide (Vyleesi)	2019	15 million	Low, primarily U.S.
Flibanserin (Addyi)	2015	~60 million	Larger market share, but plateaued

Vyleesi's slow sales reflect limited uptake despite FDA approval. Flibanserin, the first FDA-approved drug for HSDD, faced similar hurdles but has historically achieved greater market share due to longer presence and broader marketing.

Financial Outlook:

Analysts project Vyleesi’s revenue to remain modest unless marketing efforts expand, or additional indications are approved. The company has not disclosed any significant pipeline updates or major market expansion strategies.

What Is the Regulatory and Patent Status and Its Impact on Financial Outlook?

Vyleesi’s patent life extends into the late 2030s, providing a period of exclusivity. However, patent challenges or generic competition could emerge, especially if biosimilar peptides enter the market. Regulatory approval in Europe or Asia remains pending, which could unlock revenue growth.

How Might Market Dynamics Evolve in the Next Five Years?

• Expansion into additional indications: If clinical trials reveal efficacy for other sexual dysfunctions or related conditions, sales could increase.

• Increased physician education and patient awareness: Targeted marketing campaigns may improve adoption rates.

• Market competitors’ activity: New drugs or formulations could challenge the current market. Biosimilars or oral alternatives would alter the competitive landscape.

• Pricing and reimbursement: Secure reimbursement partnerships are vital for broader access, influencing revenue potential.

What Are the Risks and Opportunities for Investors and R&D Teams?

Risks:

• Limited compliance due to side effects or subcutaneous administration complexity.
• Competition from oral therapies in development.
• Regulatory delays or denials outside North America.

Opportunities:

• Growing acceptance of female sexual health treatments.
• Development of next-generation formulations with improved safety profiles.
• Expansion into international markets.

---

Key Takeaways

• Bremelanotide acetate remains a niche product with minimal sales, primarily in the U.S.
• Market growth hinges on increasing physician awareness and expanding indications.
• Competitive landscape favors newer, oral options, putting pressure on Vyleesi’s market share.
• Patent protection provides long-term exclusivity, but biosimilars could pose future threats.
• Significant revenue growth potential exists if marketing strategies succeed, clinical trials expand indications, or new markets open.

---

FAQs

1. What are the main competitors to bremeletonide acetate in treating female sexual dysfunction?
Flibanserin (Addyi) is the primary competitor. It was approved in 2015 and has a broader market presence but faces safety and efficacy debates.

2. How does bremeletonide acetate’s safety profile impact its market potential?
Side effects like nausea, headache, and cardiovascular risks limit patient compliance and prescribing, constraining sales growth.

3. What regulatory hurdles could affect the future of bremeletonide acetate?
Approval delays in Europe and Asia, regulatory scrutiny over safety data, or restrictions on use could limit market expansion.

4. Are there potential formulations that could improve the drug’s marketability?
Oral formulations or longer-acting injectable versions could enhance convenience, increasing adoption.

5. How does pricing influence bremeletonide acetate’s market success?
High treatment costs and insurance reimbursement challenges restrict patient access, limiting sales potential.

---

References

[1] IQVIA National Sales Perspectives. 2022.
[2] U.S. Food and Drug Administration. FDA Label for Vyleesi (bremelanotide). 2019.
[3] EvaluatePharma. 2022. Female sexual dysfunction market data.